A Monotherapy in Subjects With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics Profiles, and Preliminary
Efficacy of 3D185 Monotherapy in Subjects with Advanced Solid Tumors
Phase:
Phase 1
Details
Lead Sponsor:
3D Medicines (Beijing) Co., Ltd. 3D Medicines (Sichuan) Co., Ltd.